Dabigatran falsely elevates point of care international normalized ratio results

American Journal of Medicine

Volumn 124, Issue 9, 2011, Pages e5-

  Deremer, Christina E ^a   Gujral, Jaspal S ^b   Thornton, John W ^a   Sorrentino, Robert A ^a  

^a MCG Health Inc   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; DABIGATRAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; BLOOD EXAMINATION; CASE REPORT; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LETTER; MALE; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

EID: 80052030287     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.02.009     Document Type: Letter

References (2)

1. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
2. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilatea novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 116 127 Epub 2010 Mar 29